A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)

NCT04640077 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

95

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Cognitive Impairment

Interventions

OTHER: No Intervention
DRUG: donanemab

Sponsor

Eli Lilly and Company